AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of “Buy” from Analysts

AtriCure, Inc. (NASDAQ:ATRC) has been given a consensus recommendation of “Buy” by the nine research firms that are currently covering the company, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $50.8889.

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 30th. BTIG Research set a $54.00 price objective on shares of AtriCure in a research note on Wednesday, July 30th. Finally, Wall Street Zen raised shares of AtriCure from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd.

Insider Transactions at AtriCure

In other news, insider Vinayak Doraiswamy sold 2,500 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total value of $91,450.00. Following the sale, the insider owned 71,872 shares of the company’s stock, valued at approximately $2,629,077.76. This represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Regina E. Groves sold 2,452 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total transaction of $90,282.64. Following the completion of the sale, the director directly owned 33,715 shares in the company, valued at approximately $1,241,386.30. The trade was a 6.78% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,952 shares of company stock valued at $546,733. 3.50% of the stock is owned by insiders.

Institutional Investors Weigh In On AtriCure

Several large investors have recently made changes to their positions in ATRC. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in AtriCure by 170.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,196,914 shares of the medical device company’s stock worth $70,872,000 after acquiring an additional 1,385,544 shares during the last quarter. Nuveen LLC bought a new stake in AtriCure during the 1st quarter worth about $30,666,000. Jennison Associates LLC bought a new stake in AtriCure during the 1st quarter worth about $19,139,000. Osterweis Capital Management Inc. bought a new stake in AtriCure during the 1st quarter worth about $9,536,000. Finally, Millennium Management LLC grew its holdings in AtriCure by 79.2% during the 1st quarter. Millennium Management LLC now owns 623,323 shares of the medical device company’s stock worth $20,108,000 after acquiring an additional 275,487 shares during the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

NASDAQ:ATRC opened at $34.63 on Tuesday. The stock has a market cap of $1.72 billion, a P/E ratio of -44.97 and a beta of 1.62. AtriCure has a one year low of $25.57 and a one year high of $43.11. The company has a fifty day moving average price of $34.41 and a 200 day moving average price of $33.42. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The company had revenue of $136.14 million during the quarter, compared to analysts’ expectations of $130.17 million. During the same quarter in the prior year, the company posted ($0.17) EPS. The business’s revenue was up 17.1% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.390–0.340 EPS. Analysts anticipate that AtriCure will post -0.6 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.